Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Deleu
Dirk
D
Hanssens
Yolande
Y
D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003042:Cocaine / Q000031:analogs & derivatives; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives; D015259:Dopamine Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D004386:Duodenum; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007260:Infusion Pumps; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D007211:Indoles; D019275:Radiopharmaceuticals; C046649:ropinirole; C043437:fluorodopa F 18; D007980:Levodopa; C069723:2beta-carbomethoxy-3beta-(4-iodophenyl)tropane; D004295:Dihydroxyphenylalanine; D003042:Cocaine